Active Biotech AB – Interim Report January – June 2018
Second quarter in brief
- The company’s partner NeoTX presented new preclinical data for ANYARA at the AACR Annual Meeting in Chicago
- The rights issue in April brought the company SEK 47.1 M
Events after the end of the period
- The company announced that the Phase II LEGATO-HD trial evaluating efficacy and safety of laquinimod in Huntington’s disease (HD) did not meet its primary endpoint to slow the progression of the disease. However, the secondary endpoint, reduction of brain atrophy, was met. Laquinimod showed excellent safety in the study
- The company is initiating a scientific collaboration with the Wistar Institute in Philadelphia, PA, around tasquinimod to support future clinical development in multiple myeloma
|SEK M||Apr-Jun||Jan-Jun||Full year|
|Loss after tax||-9.1||-24.4||-19.3||-40.2||-108.8|
|Earnings per share (SEK)||-0.07||-0.20||-0.15||-0.33||-0.89|
|Cash and cash equivalents (at close of period)||45.6||47.7||25.2|
For further information, please contact:
| Helén Tuvesson, CEO
Tel: +46 (0)46 19 21 56
Hans Kolam, CFO
| Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund
Tel: +46 (0)46 19 20 00
The report is also available at www.activebiotech.com.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire